ECE2022 Eposter Presentations Endocrine-Related Cancer (61 abstracts)
Frequency of CYP1B1 gene polymorphism in obese and non-obese women with hormone-dependent endometrial cancer
Dusan Ilic 1 , Sanja Ognjanovic 1 , Bojana Popovic 1 , Valentina Elezovic 1 , Milica Opalic 2 , Lena Radic 1 & Djuro P. Macut 1
1Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Department for Endocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia; 2Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, Department for Endocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia
Aim: There is a significant link between the increased activity of estrogen and its metabolites in endometrial carcinogenesis. Polymorphisms of the gene involved in metabolism of estrogen can modulate risk for the development of endometrial cancer. CYP1B1 plays an important role in estrogen metabolism. In our study, the frequency of three CYP1B1 gene polymorphisms (4326 C> G, 4390 A> G and 355 G> T) were studied in obese and non-obese women with endometrioid endometrial carcinoma and healthy controls.
Methods: Genotype were determined in DNA from peripheral blood lymphocytes of 44 women with endometrial cancer and 47 healthy age-matched controls by restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR).
Results: Polymorphism 4326 C>G was verified in 70.5% of women with endometrial carcinoma and 59.6% of healthy controls (P=0.277). In the group of women with endometrial cancer, polymorphism 4326 C>G was verified in 72.2% obese and 69.2% of non-obese women (P=0.831). Polymorphism 4390 A>G was verified in 38.6% of women with endometrial carcinoma and 34.0% of healthy controls (P=0.649). In the group of women with endometrial cancer, polymorphism 4390 A>G was verified in 27.8% obese and 46.2% of non-obese women (P=0.218). Polymorphism 355 G>T was verified in 43.2% of women with endometrial carcinoma and 59.6% of healthy controls (P=0.118). In the group of women with endometrial cancer, polymorphism 355 G>T was verified in 44.4% obese and 42.3% of non-obese women (P=0.888).
Conclusion: There was no statistically significant difference in the frequency of the CYP1B1 gene polymorphism in our group of women with endometrial carcinoma and healthy controls and in women with endometrial carcinoma irrespectively of their body mass index.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more